Market Research Report :Oncology Pharmaceuticals Market in India 2012

8/2/2019 Market Research Report :Oncology Pharmaceuticals Market in India 2012

http://slidepdf.com/reader/full/market-research-report-oncology-pharmaceuticals-market-in-india-2012 1/11

‐

August 2011

1

April 2012



Executive Summary

Oncology pharmaceuticals

market

in

India

is

valued

at

INR

x

bn

in

20—

Fourth largest in volume, eighth largest in value in the world market

Market is expected to grow at a CAGR of y% from20‐‐‐‐‐

Market

r vers: Increasing number of cancer cases

Changes in

the

treatment

scenario

Development of alternative cancer

therapies

a enges: Increased competition

Drug patents

problem

Drug Portfolio managementDrivers

and

Challenges

Increase in cancer insurances

Increase in FDI

Government

Reforms in

tax

structure

Reduction in drug prices

Drug regulation

Initiatives Public –Private Partnership (PPP) programmes

Drug control programmes

Phases of clinical trial

and patents

Patents

Com etition

Highly fragmented market with large number of players

Major public players in the market include Company A,Company B, Company C, Company D,

2ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT

, , , , ,

Major private

companies

include

Company

K,

Company

L,

Company

M



•Drivers &

Challenges

• overnmen n a ves

•Market Value

Chain,

Regulation

and

•Competition

• ra eg c

ecommen a on

•Appendix

3ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPTONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT



Indian oncology pharma market has grown enormously over

the last few years

•Fourth largest in volume, eighth largest in

value in the world market

Indian market

‐overview Market

size

50

INR unit

g

•Expected to reach INR y bn in 20‐‐

•Cancer is

the

second

largest

cause

of

death

in

the country 10

20

30

m%f

e

dcba

Program (NCRP) there are z mn cancer

patients at any point of time

•There occurs X cancer related deaths each Increase

in

Cancer

Cases

20‐‐ 20‐‐e20‐‐e20‐‐e20‐‐e20‐‐e20‐‐

year

•Oral and lung cancer are the most common in

males, while in females, cervical, followed by

breast

and

ovarian

cancer

are

the

most

800

1,000

1,200

In ‘000

n%

common

•Availibilty of xx oncologists per yy people in

India0

200

400

600

‐‐

x

‐‐

y


Source:



A huge volume of cancer drugs is exported to many

countries…

• Highly fragmented market with many domestic

manufacturers lead to huge volume of exports

Exports of

Oncological

Pharmaceuticals Total

Exports

4,000

INR units

e5

• India currently exports to more than 115 countries

• Between 20

‐‐ ‐20

‐‐and

20

‐‐ ‐20

‐‐the

value

of

export

of oncology pharmaceuticals rose by m%1 000

2,000

3,000

e2e1

P% e4

e3

• Country A accounted for the highest exports in 20‐‐ ‐

20‐‐ while Country B ranked highest in 20‐‐ ‐ 20‐‐

Ex orts – Re ion wise 20‐‐ ‐ 20‐‐ Ex orts – Re ion wise 20‐‐ ‐ 20‐‐

0

20– to 20‐‐20–to 20‐‐ 20– to 20‐‐20– to 20‐‐20– to 20‐‐

A1%

G2%

A2%Country B

Country A

D1%

E1% B1% E2%

D2%

B2%

Country F

Country D

Country E

5ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPTONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT

Note: All figures are for financial year Source: Ministry of Commerce: Export‐Import Data Bank

F2%Country G



Drivers & Challenges ‐ Summary

Drivers

Challenges

Increased competition

Increasing number of cancer cases

Changes

in

the

treatment

scenario

Drug patent problems

Drug portfolio

management

eve opmen o a erna ve cancer

therapies

Increase in cancer insurances

Lack of affordability

Increase in the amount of FDI




Government initiatives

Reforms in tax structure Public-Private-partnership(PPP) projects

Government

Initiative

Cancer control programmes Reduction in drug prices




Public: Domestic Company – Company A (1/3)

Company Information Offices and Centres – India

Corporate AddressX RoadBangalore

.

Fax No. +91 xx xxxxx xxxxx

Website www.ppp.com

Year of19--

Products and Services

Ticker Symbol xxxxxx

Stock Exchange NNN

Products and Services

Key People

Head Office

Category Products/Services

Pharmaceutical

CVD, oncology, CNS, respiratory,

dermatology,

orthopedics,

nutritional,

Person M Founder

Person N CFO

Person O Head

uro ogy, anti‐in ectives

Molecule

Development

Infectious diseases, metabolic diseases,

inflammatory/respiratory diseases, and

oncology


Person Q President

Source:



Public: Domestic Company – Company B (2/3)

Key Ratios

Profit / Loss

RevenueProfit

INR mn

p

Revenue

INR mn

rq10,000

Particulars y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐

Profitability RatiosOperating Margin

Financial Snapshot

n

0‐m0

20‐‐

tp

20‐‐

s

o

20‐‐

n

20‐‐

m

5,000

Net Margin

Profit Before Tax Margin

Return on Equity

Return on Capital Employed

Return on Working Capital

Return on Assets

Financial Summary

• The company incurred a net loss of INR xx mn in FY 20‐‐, as

compared to net profit of INR yy mn in FY 20‐‐

• The company reported total income of INR xx bn in FY 20‐‐,

Return on Fixed Assets

Cost RatiosOperating costs (% of Sales)

Administration

costs

(%

of

Sales)

Interest costs % of Sales ‐‐

• The company earned an operating margin of x per cent in FY 20‐‐ a

decrease of y percentage points over FY 20‐‐

• The company reported debt to equity ratio of x in FY 20‐‐, an

increase of y per cent over FY 20‐‐

Liquidity RatiosCurrent Ratio

Cash Ratio

Leverage RatiosDebt

to

Equity

Rationanc a

ummary

Indicators Present Value

Market Capitalization (INR) X units

Total Enterprise Value (INR) Y units

Debt to Capital Ratio

Interest Coverage Ratio

Efficiency RatiosFixed Asset Turnover

Asset Turnover

Current Asset Turnover


Source:

PE Ratio (Absolute) A Working

Capital

TurnoverCapital Employed Turnover

Improved Decline



Public: Domestic Company – Company C (3/3)

onm

Key Business Segments

x y z

Key Geographic Segments

y

xxx

y

x

z

y

x

z

y

x

z

y

x

z

y

x

20‐‐

z

20‐‐

z

20‐‐

z

20‐‐20‐‐20‐‐20‐‐20‐‐

Key Recent

Developments

Descr pt on News

Overview• Company A is an integrated research based company that produces a wide range of generic medicines

• Serves customers in over 100 countries with manufacturing facilities in several countries

Oncology Pharmaceuticals • Products include include Product 1 and Product 2

Key Initiatives• Is making consistent effort for continual improvement in rural areas with respect to accessibility of

medicines


Source:



Thank you for the attentionThe Oncology Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Industry

Series.

For more detailed information or customized research requirements please contact:

“ ”

Contact Number: +91 33 4064 6214

E‐Mail: [email protected]

. .

emerging markets. Track our new releases and major updates in these industries on

About Netscribes

Netscribes is

a knowledge

‐consulting

and

solutions

firm

with

clientele

across

the

globe.

The

company’s

expertise

spans

areas

of

investment

&

business research, business & corporate intelligence, content ‐management services, and knowledge‐software services. At its core lies a true

value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth

objectives.


. ,

Pvt. Ltd.

or

“Netscribes”

is

not

responsible

for

any

loss

or

damage

arising

from

use

of

this

document.

This

document

is

the

sole property

of

Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.

Market Research Report :Oncology Pharmaceuticals Market in India 2012

Documents